Dr. Brandon McNaughton, Chief Executive Officer and Co-Founder of Akadeum
CAR T Cell Therapy Is Offering Life-lines to Cancer Patients, but Only to Those Who Can Afford It | By Dr. Brandon McNaughton, Chief Executive Officer and Co-Founder of Akadeum
The creation of CAR T cell therapy begins with collection of the patient’s blood and separation of the lymphocytes. These include T cells, B cells, and innate lymphoid cells, all of which are separated through apheresis (leukapheresis). It is this separation process which, if optimized, has the potential to revolutionize immunotherapy treatments for cancer patients.